| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Research and development | 2,066,825 | 2,565,244 | 2,878,529.5* | 2,177,922 |
| General and administrative | 2,839,763 | 3,140,712 | 2,454,900* | 3,294,456 |
| Total operating expenses | 4,906,588 | 5,705,956 | 5,333,429.5 | 5,472,378 |
| Loss from operations | -4,906,588 | -5,705,956 | -5,333,429.5* | -5,472,378 |
| Change in estimated fair value of warrant liability | - | - | 0* | 0 |
| Gain on settlement of warrants | - | - | 0* | 0 |
| Loss on issuance of related party convertible notes payable at fair value | - | - | 0* | 0 |
| Change in estimated fair value of related party convertible notes payable | - | - | 0* | 0 |
| Interest expense | 5,063 | 5,062 | 5,062.5* | 5,063 |
| Interest income | 45,016 | 85,269 | 145,952.5* | 69,971 |
| Total other income, net | 39,953 | 80,207 | 140,890* | 64,908 |
| Net loss | -4,866,635 | -5,625,749 | -5,192,539.5 | -5,407,470 |
| Basic EPS | -0.2 | -0.24 | -0.236 | -0.25 |
| Diluted EPS | -0.2 | -0.24 | -0.236 | -0.25 |
| Basic Average Shares | 23,871,850 | 23,537,134 | 22,024,011 | 21,394,965 |
| Diluted Average Shares | 23,871,850 | 23,537,134 | 22,024,011 | 21,394,965 |
ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC. (ACTU)